全文获取类型
收费全文 | 14758篇 |
免费 | 1093篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 203篇 |
儿科学 | 248篇 |
妇产科学 | 201篇 |
基础医学 | 2211篇 |
口腔科学 | 158篇 |
临床医学 | 1521篇 |
内科学 | 3608篇 |
皮肤病学 | 388篇 |
神经病学 | 1413篇 |
特种医学 | 645篇 |
外国民族医学 | 10篇 |
外科学 | 2305篇 |
综合类 | 41篇 |
一般理论 | 5篇 |
预防医学 | 678篇 |
眼科学 | 198篇 |
药学 | 942篇 |
中国医学 | 14篇 |
肿瘤学 | 1127篇 |
出版年
2024年 | 18篇 |
2023年 | 161篇 |
2022年 | 279篇 |
2021年 | 644篇 |
2020年 | 345篇 |
2019年 | 536篇 |
2018年 | 646篇 |
2017年 | 414篇 |
2016年 | 474篇 |
2015年 | 544篇 |
2014年 | 724篇 |
2013年 | 862篇 |
2012年 | 1303篇 |
2011年 | 1281篇 |
2010年 | 694篇 |
2009年 | 629篇 |
2008年 | 961篇 |
2007年 | 933篇 |
2006年 | 797篇 |
2005年 | 742篇 |
2004年 | 635篇 |
2003年 | 541篇 |
2002年 | 472篇 |
2001年 | 104篇 |
2000年 | 103篇 |
1999年 | 90篇 |
1998年 | 87篇 |
1997年 | 59篇 |
1996年 | 59篇 |
1995年 | 56篇 |
1994年 | 45篇 |
1993年 | 39篇 |
1992年 | 56篇 |
1991年 | 66篇 |
1990年 | 56篇 |
1989年 | 52篇 |
1988年 | 38篇 |
1987年 | 37篇 |
1986年 | 33篇 |
1985年 | 20篇 |
1984年 | 26篇 |
1983年 | 31篇 |
1982年 | 34篇 |
1981年 | 14篇 |
1980年 | 15篇 |
1979年 | 18篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1974年 | 14篇 |
1972年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
In human cortex and hippocampus area, [3H]5-HT (5 nM) labels 5-HT1A, 5-HT1D and 5-HT1E sites. After masking 5-HT1A receptors by 0.1 μM 8-OH-DPAT, the binding displaced by 0.1 μM 5-CT presumably represented 5-HT1D sites and the remaining binding 5-HT1E sites. In frontal cortex, 5-HT1A receptors represented the main binding in layers II and VI and a lower fraction on other layers. 5-HT1D and 5-HT1E sites, were more homogeneously distributed in layers II to VI (21–34% of specific [3H]5-HT binding). 5-HT1E sites were of similar affinities (KD close to 6–8 nM) in the cortical layers II to VI. In CA1 field of hippocampus, (pyramidal layer, stratum radiatum, molecular layer), CA2 and dentate gyrus, 5-HT1A receptors represented the major fraction, 5-HT1D sites a significant fraction and 5-HT1E a minor fraction of the specific [3H]5-HT binding. In CA3–CA4 fields, 5-HT1A receptors were less densely present, 5-HT1D sites were predominant and 5-HT1E sites represented a significant fraction (27%). The highest densities of 5-HT1E sites have been measured in subiculum, where 5-HT1A, 5-HT1D, and 5-HT1E binding sites were equally represented and in entorhinal cortex where 5-HT1E sites represented the major binding in layer III. They were also present in layers II and IV (29 and 24%) and, to a lesser extent, in layers V and VI. 5-HT1A sites were predominant in layer VI, II and V and were less abundant in other layers. 5-HT1D were homogeneously present in layers II, III, IV and were present in low amounts in other layers. No 5-HT1E were detected in choroid plexus, where [3H]5-HT was dramatically reduced by mesulergine (5-HT2C receptors). No significant displacement of [3H]5-HT by mesulergine was measured in other structures. 相似文献
42.
43.
Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. 总被引:13,自引:0,他引:13
Marc Levivier Nicolas Massager David Wikler José Lorenzoni Salvador Ruiz Daniel Devriendt Philippe David Fran?oise Desmedt Stéphane Simon Paul Van Houtte Jacques Brotchi Serge Goldman 《Journal of nuclear medicine》2004,45(7):1146-1154
We developed a technique that allows the routine integration of PET in stereotactic neurosurgery, including radiosurgery. We report our clinical experience with the combined use of metabolic (i.e., PET) and anatomic (i.e., MRI and CT) images for the radiosurgical treatment of brain tumors. We propose a classification describing the relative role of the information provided by PET in this multimodality image-guided approach. METHODS: Between December 1999 and March 2003, 57 patients had stereotactic PET as part of their image acquisition for the planning of gamma knife radiosurgery. Together with stereotactic MRI and CT, stereotactic PET images were acquired on the same day using either (18)F-FDG or (11)C-methionine. PET images were imported in the planning software for the radiosurgery dosimetry, and the target volume was defined using the combined information of PET and MRI or CT. To analyze the specific contribution of the PET findings, we propose a classification that reflects the strategy used to define the target volume. RESULTS: The patients were offered radiosurgery with PET guidance when their tumor was ill-defined and we anticipated some limitation of target definition on MRI alone. This represents 10% of the radiosurgery procedures performed in our center during the same period of time. There were 40 primary brain lesions, 7 metastases, and 10 pituitary adenomas. Abnormal PET uptake was found in 62 of 72 targets (86%), and this information altered significantly the MRI-defined tumor in 43 targets (69%). CONCLUSION: The integration of PET in radiosurgery provides additional information that opens new perspectives for the optimization of the treatment of brain tumors. 相似文献
44.
Orlando Parise Franois Janot Bernard Luboinski Liliane Massaad Nicolas Albin Caroline Toussaint Marie-Ange Verjus Marc Bonnay Alain Gouyette Guy G. Chabot 《Head & neck》1994,16(2):158-164
Background. Head and neck squamous cell carcinomas (HNSCC) present variable aggressiveness and chemosensitivity. Because the glutathione (GSH) system and thymidylate synthase (TS) are involved in the resistance to the main drugs used in HNSCC (cisplatin and 5-FU), we studied these systems in tumors and normal mucosae. Methods. Tumor samples and normal adjacent mucosae were collected from 37 untreated HNSCC patients. GSH and glutathione S-transferase (GST) activity were assayed by spectrophotometry, whereas TS activity and folates were determined by radioassays. Results. Mean GSH levels were higher in tumors (15.2 ± 8.2 nmol/mg protein) than in mucosae (8.3 ± 4.1 nmol/mg protein) (p = 0.005, paired t test). GST activity was also higher in tumors (394 ± 194 nmol/min/mg protein) than in mucosae (261 ± 132 nmol/min/mg protein) (p = 0.0003). TS activity was markedly higher in tumors (9.2 ± 21.5 pmol/min/mg protein) compared to that of mucosae (0.9 ± 1.2 pmol/min/mg protein) (p = 0.0001). Folate levels in tumors and mucosae were similar (1.2 ± 1.1 and 0.8 ± 0.9 pmol/mg protein, respectively; p = 0.1, NS). In relation to clinical stage and tumor size, a statistical difference was found in GSH and GST values between tumors and mucosae for stage IV and T3/T4. The increase in tumor TS compared to that of mucosae was significant for all clinical stages, tumor sizes, and nodal involvement. Conclusions. These data enhance our understanding of the enzymatic systems involved in cisplatin and 5-fluorouracil (5-FU) resistance in HNSCC and normal mucosae and may help to elucidate tumor behavior and interpatient differences in drug sensitivity. © 1994 John Wiley & Sons, Inc. 相似文献
45.
R Andrianne C Vandeberg P Bonnet H Nicolas L Coppens C Bouffioux J de Leval 《European urology》1992,22(2):134-136
Extracorporeal shockwave lithotripsy (ESWL) has been initially designed for stones located in the kidney and the upper ureter. Our lithotripter is no exception. Its components (the table and the orientation of the semi-ellipsoid reflector) are adapted for the treatment of kidney or lumbar ureter stones. However, the elements forming the unit of treatment (the table, the C-arm and the Tripter) can be modified in such a way that focalization of stones of the lower ureter becomes possible through a perineal exposure. The aim is to avoid the pelvic bone shield while a good focalization of the stone is realized. From June 1989 to March 1991, 35 patients were treated for distal ureteric stones by ESWL in this original positioning. 相似文献
46.
Glutamine synthetase (L-glutamate:ammonia ligase; EC 6.3.1.2), an enzyme catalysing the ATP-dependent formation of glutamine from glutamate and ammonia, was detected immunocytochemically only in glial (interstitial) cells of the superficial pineal gland of the rat. The results show the important role of pineal glial cells in the metabolism of the presumptive neurotransmitters, glutamate and gamma-aminobutyric acid (GABA) as well as in detoxification of ammonia. 相似文献
47.
48.
Siamak Mohammadi Giuseppe Silvaggio Nicolas Bonnet George Berberian Richard Dorent Marc Bikter Alain Pavie Iradj Gandjbakhch 《The Journal of heart and lung transplantation》2005,24(8):995-997
BACKGROUND: We have noted an unexpectedly high incidence of prostate cancer in our heart transplant recipients (HTR). METHODS: We conducted a retrospective review of patients after heart transplantation to investigate the prevalence, treatment, and outcome of prostate cancer diagnosed after systematic screening (study group). We compared them with case-matched HTR (control). RESULTS: Among 702 recipients, 15 patients had elevated prostate-specific antigen (PSA) levels. Fourteen cases of prostate cancer were diagnosed and treated. The median time between transplantation and prostate cancer diagnosis was 73 months. No patient was diagnosed in a locally advanced (>T2) or metastatic stage. Eleven patients (78.6%) received curative treatment. During follow-up (median, 44 months), 1 patient died from prostate cancer. The survival rate between the study and control groups did not differ. CONCLUSION: Routine PSA testing is recommended as a screening test for prostate cancer in patients after heart transplantation. We believe this could also result in detection of early stages of prostate cancer, thus allowing curative treatment, and achieving similar survival to other case-matched HTR with no prostate cancer. 相似文献
49.
50.
Stéphane Aubert Roland Henaine Olivier Raisky Nicolas Chavanis Jacques Robin René Ecochard Jean Ninet 《European journal of cardio-thoracic surgery》2005,28(2):223-228
OBJECTIVE: We consider the short- and long-term outcomes of the repair of the isolated partial atrioventricular (AV) septal defect to determine the role played by the atypical forms on the initial AV valve replacement and on the risk of reoperation. METHODS: Two hundred and eight patients underwent an operation for this malformation between 1974 and 2001. Clinical and echocardiographic examinations were performed on all patients, the AV valve regurgitation was graded from 1 to 4 and a residual interatrial shunt was sought. Median age at the intervention was 5.8 years (3 months to 67 years). RESULTS: Median follow-up time was 7.5 years (range 0-22.6 years). The cumulative 30-day, 5- and 20-year survival rates were 96.5, 95.4 and 94.6%, respectively. AV valve replacement was associated with a high mortality (P<0.001). A reoperation was performed on 12 patients (5.7%) including six patients within less than a 30-day period, especially to repair residual AV valve regurgitation. We performed four AV valve repairs by annuloplasty and six AV valve replacements. Two patients who had initially undergone an AV valve replacement underwent a reoperation for valve thrombosis. The cumulative 30-day, 5- and 20-year rates of freedom from reoperation were 96.5, 93.6 and 83%, respectively. An atypical form was present in 24 patients (11.5%) and was a risk factor for initial AV valve replacement (P<0.001) and for reoperation (P<0.001). A complete AV block occurred in 13 patients (6.2%), all of them within a 30-day period. The AV valve replacement was a high risk factor for a complete AV block (P<0.001). At the end of our study 180 patients (96%) were in NYHA I and 8 in NYHA II. CONCLUSIONS: The morbi-mortality of the isolated partial AV septal defect is primarily perioperative and is linked with the presence of an atypical form of the lesion. This atypical form was the main reason for reoperation for AV valve regurgitation. The AV valve replacement was associated with a high mortality and with the occurrence of complete AV block. Using a standardized technique, the AV septal defect can be repaired with excellent long-term clinical and echographic results. 相似文献